DENVER — Gov. Jared Polis said Tuesday the state's future vaccine supply depends, in part, on the federal government but also the U.S. Food and Drug Administration (FDA) approval of other vaccines.
UCHealth researchers hope their study of the AstraZeneca vaccine will contribute to FDA approval in the near future, but doctors expressed a need for more trial participants of color.
“There’s a long history in research where we’ve had underrepresented populations, and so there’s been a big push to include diverse populations so we really know what’s happening — not only gender wise but also race wise — so when we make drugs or make vaccines, we’ll be treating everyone not just a few people,” said Dr. Gary Luckasen of UCHealth.
The AstraZeneca study is the second COVID-19 vaccine to launch at UCHealth.
Currently, the healthcare system has about 1,100 participants enrolled with the hop to enroll more individuals through Jan. 13, at the least.
Nationwide, the trial has around 25,000-26,000 participants.
If interested in participating, click here.
